TY - JOUR
T1 - Corticobasal degeneration
T2 - key emerging issues
AU - Ali, F.
AU - Josephs, K. A.
N1 - Publisher Copyright:
© 2017, Springer-Verlag GmbH Germany.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Corticobasal degeneration (CBD) was first described by Rebeiz et al. in 1967, and was called corticodentatonigral degeneration with neuronal achromasia [1]. Since then, our knowledge of the clinical features and underlying tau pathology has grown tremendously. Clinical antemortem diagnosis of CBD pathology remains challenging and has led to the development of revised diagnostic criteria. As various clinical phenotypes may have CBD pathology, accurate prevalence studies are lacking. Recently, pooled prevalence of fronto-temporal lobar degeneration, PSP and CBS was reported as 10.6 per 100,000 [2]. Although rare, CBD is an important disease to understand because it provides a model of a specific proteinopathy (tauopathy) and, therefore, opportunity to study pathophysiology of tauopathies and efficacy of tau-directed therapies. In the past few years, identification of tau specific ligands has advanced neuroimaging of tauopathies such as CBD and progressive supranuclear palsy. However, clinical prediction of CBD pathology remains challenging and an active are of research. In this review, we highlight key emerging issues in CBD pathophysiology, genetics and novel neuroimaging techniques with tau ligands.
AB - Corticobasal degeneration (CBD) was first described by Rebeiz et al. in 1967, and was called corticodentatonigral degeneration with neuronal achromasia [1]. Since then, our knowledge of the clinical features and underlying tau pathology has grown tremendously. Clinical antemortem diagnosis of CBD pathology remains challenging and has led to the development of revised diagnostic criteria. As various clinical phenotypes may have CBD pathology, accurate prevalence studies are lacking. Recently, pooled prevalence of fronto-temporal lobar degeneration, PSP and CBS was reported as 10.6 per 100,000 [2]. Although rare, CBD is an important disease to understand because it provides a model of a specific proteinopathy (tauopathy) and, therefore, opportunity to study pathophysiology of tauopathies and efficacy of tau-directed therapies. In the past few years, identification of tau specific ligands has advanced neuroimaging of tauopathies such as CBD and progressive supranuclear palsy. However, clinical prediction of CBD pathology remains challenging and an active are of research. In this review, we highlight key emerging issues in CBD pathophysiology, genetics and novel neuroimaging techniques with tau ligands.
KW - AV-1451
KW - Corticobasal degeneration
KW - Corticobasal syndrome
KW - Tau-PET
UR - http://www.scopus.com/inward/record.url?scp=85031939499&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031939499&partnerID=8YFLogxK
U2 - 10.1007/s00415-017-8644-3
DO - 10.1007/s00415-017-8644-3
M3 - Article
C2 - 29063240
AN - SCOPUS:85031939499
SN - 0340-5354
VL - 265
SP - 439
EP - 445
JO - Journal of Neurology
JF - Journal of Neurology
IS - 2
ER -